1.Effects of two medicinal plants Psidium guajava L. (Myrtaceae) and Diospyros mespiliformis L. (Ebenaceae) leaf extracts on rat skeletal muscle cells in primary culture
R.G BELEMTOUGRI ; B CONSTANTIN ; C COGNARD ; G RAYMOND ; L SAWADOGO
Journal of Zhejiang University. Science. B 2006;7(1):56-63
Crude decoction, aqueous and ethanolic extracts of two medicinal plants (Psidium guajava and Diospyros mespiliformis), widely used in the central plateau of Burkina Faso to treat many diseases were evaluated for their antagonistic effects on caffeine induced calcium release from sarcoplasmic reticulum of rat skeletal muscle cells. These different extracts showed a decrease of caffeine induced calcium release in a dose dependent manner. Comparison of the results showed that Psidium guajava leaf extracts are more active than extracts ofDiospyros mespiliformis and that crude decoctions show better inhibitory activity.The observed results could explaine their use as antihypertensive and antidiarrhoeal agents in traditional medicine, by inhibiting intracellular calcium release.
2.Mechanical Thrombectomy Versus Intravenous Thrombolysis in Distal Medium Vessel Acute Ischemic Stroke: A Multinational Multicenter Propensity Score-Matched Study
Hamza Adel SALIM ; Vivek YEDAVALLI ; Basel MUSMAR ; Nimer ADEEB ; Muhammed Amir ESSIBAYI ; Kareem El NAAMANI ; Nils HENNINGER ; Sri Hari SUNDARARAJAN ; Anna Luisa KÜHN ; Jane KHALIFE ; Sherief GHOZY ; Luca SCARCIA ; Benjamin Y.Q. TAN ; Benjamin PULLI ; Jeremy J. HEIT ; Robert W. REGENHARDT ; Nicole M. CANCELLIERE ; Joshua D. BERNSTOCK ; Aymeric ROUCHAUD ; Jens FIEHLER ; Sunil SHETH ; Ajit S. PURI ; Christian DYZMANN ; Marco COLASURDO ; Xavier BARREAU ; Leonardo RENIERI ; João Pedro FILIPE ; Pablo HARKER ; Razvan Alexandru RADU ; Thomas R. MAROTTA ; Julian SPEARS ; Takahiro OTA ; Ashkan MOWLA ; Pascal JABBOUR ; Arundhati BISWAS ; Frédéric CLARENÇON ; James E. SIEGLER ; Thanh N. NGUYEN ; Ricardo VARELA ; Amanda BAKER ; David ALTSCHUL ; Nestor R. GONZALEZ ; Markus A. MÖHLENBRUCH ; Vincent COSTALAT ; Benjamin GORY ; Christian Paul STRACKE ; Mohammad Ali AZIZ-SULTAN ; Constantin HECKER ; Hamza SHAIKH ; David S. LIEBESKIND ; Alessandro PEDICELLI ; Andrea M. ALEXANDRE ; Illario TANCREDI ; Tobias D. FAIZY ; Erwah KALSOUM ; Boris LUBICZ ; Aman B. PATEL ; Vitor Mendes PEREIRA ; Adrien GUENEGO ; Adam A. DMYTRIW ;
Journal of Stroke 2024;26(3):434-445
Background:
and Purpose The management of acute ischemic stroke (AIS) due to distal medium vessel occlusion (DMVO) remains uncertain, particularly in comparing the effectiveness of intravenous thrombolysis (IVT) plus mechanical thrombectomy (MT) versus IVT alone. This study aimed to evaluate the safety and efficacy in DMVO patients treated with either MT-IVT or IVT alone.
Methods:
This multinational study analyzed data from 37 centers across North America, Asia, and Europe. Patients with AIS due to DMVO were included, with data collected from September 2017 to July 2023. The primary outcome was functional independence, with secondary outcomes including mortality and safety measures such as types of intracerebral hemorrhage.
Results:
The study involved 1,057 patients before matching, and 640 patients post-matching. Functional outcomes at 90 days showed no significant difference between groups in achieving good functional recovery (modified Rankin Scale 0–1 and 0–2), with adjusted odds ratios (OR) of 1.21 (95% confidence interval [CI] 0.81 to 1.79; P=0.35) and 1.00 (95% CI 0.66 to 1.51; P>0.99), respectively. Mortality rates at 90 days were similar between the two groups (OR 0.75, 95% CI 0.44 to 1.29; P=0.30). The incidence of symptomatic intracerebral hemorrhage was comparable, but any type of intracranial hemorrhage was significantly higher in the MT-IVT group (OR 0.43, 95% CI 0.29 to 0.63; P<0.001).
Conclusion
The results of this study indicate that while MT-IVT and IVT alone show similar functional and mortality outcomes in DMVO patients, MT-IVT presents a higher risk of hemorrhagic complications, thus MT-IVT may not routinely offer additional benefits over IVT alone for all DMVO stroke patients. Further prospective randomized trials are needed to identify patient subgroups most likely to benefit from MT-IVT treatment in DMVO.